Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Neonatal hypoglycemia

INTRODUCTION

Transient low blood glucose levels in neonates are common as the source of glucose at delivery changes from a continuous supply from the mother to the intermittent supply from feeds. It is estimated that ten percent of normal term newborns cannot maintain a plasma glucose concentration above 30 mg/dL (1.7 mmol/L) if their first feeding is delayed for three to six hours after birth [1,2]. Although transient asymptomatic hypoglycemia in healthy infants appears to be part of the normal transition to extrauterine life, persistent or recurrent hypoglycemia can result in neurologic sequelae. (See 'Neurodevelopmental outcome' below.)


The pathogenesis, clinical manifestations, evaluation, and management of neonatal hypoglycemia will be discussed here.

DEFINITION

It has been difficult to define pathologic neonatal hypoglycemia as a precise numerical blood glucose level. Low blood glucose levels normally occur after birth, and most infants are asymptomatic despite very low blood glucose levels. However, some infants are symptomatic at the same or even higher blood glucose levels. This variability is due to a number of factors that affect the infant’s response to a decrease in blood glucose level, including the infant’s gestational age, postnatal age, the presence of other sources of energy (eg, ketone bodies), and other factors that affect glucose metabolism. Thus, the diagnosis of clinically significant hypoglycemia is dependent on the clinical setting and cannot solely be based on a specific blood glucose level.

Ideally, neonatal hypoglycemia would be defined as the blood glucose concentration at which intervention should be initiated to avoid significant morbidity, especially neurologic sequelae. However, this definition remains elusive because the blood glucose level and duration of hypoglycemia associated with poor neurodevelopmental outcome has not been established [3,4]. (See 'Neurodevelopmental outcome' below.)

In 2000, a consensus statement proposed the use of practical operational thresholds for glucose concentrations at which intervention should be considered [3]. These values would provide a margin of safety for the management of neonatal hypoglycemia. (See 'Management' below.)

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Mar 12, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Stanley CA, Baker L. The causes of neonatal hypoglycemia. N Engl J Med 1999; 340:1200.
  2. Lubchenco LO, Bard H. Incidence of hypoglycemia in newborn infants classified by birth weight and gestational age. Pediatrics 1971; 47:831.
  3. Cornblath M, Hawdon JM, Williams AF, et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics 2000; 105:1141.
  4. Hay WW Jr, Raju TN, Higgins RD, et al. Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr 2009; 155:612.
  5. Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127:575.
  6. Srinivasan G, Pildes RS, Cattamanchi G, et al. Plasma glucose values in normal neonates: a new look. J Pediatr 1986; 109:114.
  7. Economides DL, Proudler A, Nicolaides KH. Plasma insulin in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 1989; 160:1091.
  8. Hawdon JM, Weddell A, Aynsley-Green A, Ward Platt MP. Hormonal and metabolic response to hypoglycaemia in small for gestational age infants. Arch Dis Child 1993; 68:269.
  9. Worthen HG, al Ashwal A, Ozand PT, et al. Comparative frequency and severity of hypoglycemia in selected organic acidemias, branched chain amino acidemia, and disorders of fructose metabolism. Brain Dev 1994; 16 Suppl:81.
  10. Collins JE, Leonard JV. Hyperinsulinism in asphyxiated and small-for-dates infants with hypoglycaemia. Lancet 1984; 2:311.
  11. Sinclair JC, Bottino M, Cowett RM. Interventions for prevention of neonatal hyperglycemia in very low birth weight infants. Cochrane Database Syst Rev 2009; :CD007615.
  12. Sue CM, Hirano M, DiMauro S, De Vivo DC. Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol 1999; 23:113.
  13. Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998; 18:188.
  14. Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr 2012; 161:787.
  15. Adam PA, Räihä N, Rahiala EL, Kekomäki M. Oxidation of glucose and D-B-OH-butyrate by the early human fetal brain. Acta Paediatr Scand 1975; 64:17.
  16. de Boissieu D, Rocchiccioli F, Kalach N, Bougnères PF. Ketone body turnover at term and in premature newborns in the first 2 weeks after birth. Biol Neonate 1995; 67:84.
  17. Vannucci RC, Nardis EE, Vannucci SJ, Campbell PA. Cerebral carbohydrate and energy metabolism during hypoglycemia in newborn dogs. Am J Physiol 1981; 240:R192.
  18. Hawdon JM, Ward Platt MP, Aynsley-Green A. Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. Arch Dis Child 1992; 67:357.
  19. Balion C, Grey V, Ismaila A, et al. Screening for hypoglycemia at the bedside in the neonatal intensive care unit (NICU) with the Abbott PCx glucose meter. BMC Pediatr 2006; 6:28.
  20. Rosenthal M, Ugele B, Lipowsky G, Küster H. The Accutrend sensor glucose analyzer may not be adequate in bedside testing for neonatal hypoglycemia. Eur J Pediatr 2006; 165:99.
  21. Harris DL, Battin MR, Weston PJ, Harding JE. Continuous glucose monitoring in newborn babies at risk of hypoglycemia. J Pediatr 2010; 157:198.
  22. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Validation of the continuous glucose monitoring sensor in preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98:F136.
  23. Hay WW Jr, Rozance PJ. Continuous glucose monitoring for diagnosis and treatment of neonatal hypoglycemia. J Pediatr 2010; 157:180.
  24. Sweet DG, Hadden D, Halliday HL. The effect of early feeding on the neonatal blood glucose level at 1-hour of age. Early Hum Dev 1999; 55:63.
  25. Lilien LD, Pildes RS, Srinivasan G, et al. Treatment of neonatal hypoglycemia with minibolus and intraveous glucose infusion. J Pediatr 1980; 97:295.
  26. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24:643.
  27. Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006; 42:108.
  28. Miralles RE, Lodha A, Perlman M, Moore AM. Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. Arch Pediatr Adolesc Med 2002; 156:999.
  29. Hawdon JM, Aynsley-Green A, Ward Platt MP. Neonatal blood glucose concentrations: metabolic effects of intravenous glucagon and intragastric medium chain triglyceride. Arch Dis Child 1993; 68:255.
  30. Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. Pediatrics 2006; 117:2231.
  31. Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122:65.
  32. Tam EW, Widjaja E, Blaser SI, et al. Occipital lobe injury and cortical visual outcomes after neonatal hypoglycemia. Pediatrics 2008; 122:507.
  33. Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ 1988; 297:1304.
  34. Cornblath M, Schwartz R. Outcome of neonatal hypoglycaemia. Complete data are needed. BMJ 1999; 318:194.
  35. Kerstjens JM, Bocca-Tjeertes IF, de Winter AF, et al. Neonatal morbidities and developmental delay in moderately preterm-born children. Pediatrics 2012; 130:e265.
  36. Duvanel CB, Fawer CL, Cotting J, et al. Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. J Pediatr 1999; 134:492.
  37. Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent "hypoglycemia" in preterm infants. Pediatrics 2012; 130:e1497.